Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2007

View Archived Issues

Potential new therapies for immunological disorders reported in the patent literature

Recent patents cover HDAC inhibitors primarily for cancer

Curcumin derivative boosts immune system to clear Abeta deposits in Alzheimer's

Antiinflammatory mechanism for quinacrine identified

Altus begins phase I trial of ALTU-237 for hyperoxalurias and kidney stone prevention

Bone primary cilia: a potential target to prevent bone loss

MPA approves phase I/II study of ChronVac-C hepatitis vaccine

Romark begins phase II Alinia trial for chronic hepatitis C

Icagen partners with Pfizer in ion channel-based therapies for pain and related disorders

Oramed successfully completes oral insulin phase Ia trial

Myriad begins third phase II trial of Azixa for lung cancer spread to the brain

Positive results for Cephalon's phase III trial of Fentora for noncancer breakthrough pain

HealthLinx initiates phase II biomarker trial of Ovplex test for ovarian cancer

UCB submits MAA for Vimpat for neuropathic pain to EMEA

FDA grants fast track designation to Adventrx's CoFactor

EMEA reviews new indication for Bioenvision's Evoltra

Auxilium cleared to resume clinical trials for Xiaflex

EMEA accepts Jerini's marketing application for icatibant in HAE

Boston-based investigators focus on the identification of necroptosis inhibitors

Potent, orally active lead LTB4 hydrolase inhibitor selected at J&J

FDA approves Anesiva's innovative powder analgesic, Zingo, for use in children

XOMA-052 to enter the clinic for the treatment of type 2 diabetes

M2-selective development candidate for OAB presented by Theravance

Wyeth continues to search for potent, orally active LXR agonists with good selectivity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...